Pediatric Cardiology, Azienda Policlinico - Ospedale Pediatrico Giovanni XXIII, Bari, Italy.
J Cardiovasc Med (Hagerstown). 2013 Jan;14(1):74-5. doi: 10.2459/JCM.0b013e3283528fa9.
We report the case of a 14-year-old boy affected by Tetralogy of Fallot and pulmonary atresia, who had already undergone multiple surgical procedures. He had later developed a steno-insufficiency of the pulmonary bioprosthesis. We performed a percutaneous pulmonary valve implantation (PPVI), which is a minimally invasive treatment, as effective as conventional valve surgery and associated with less morbidity and mortality. Up to now PPVI has been carried out in patients with chronic pulmonary vascular resistance (PVR) in the presence of a right ventricular outflow tract (RVOT) patch by prior deployment of an intravascular stent as an artificial conduit that makes subsequent valve implantation possible. The peculiarity of our procedure was that we implanted the valve directly on to the annulus of the bioprosthesis (valve-in-valve), without performing a prestenting of the prosthetic valve.
我们报告了一例患有法洛四联症和肺动脉闭锁的 14 岁男孩的病例,该男孩已经接受了多次手术。他后来出现了肺动脉生物瓣狭窄-关闭不全。我们进行了经皮肺动脉瓣植入术(PPVI),这是一种微创治疗方法,与传统瓣膜手术一样有效,且发病率和死亡率更低。到目前为止,PPVI 已在存在右心室流出道(RVOT)补片的慢性肺血管阻力(PVR)患者中进行,通过预先在血管内支架上部署作为人工导管,使得随后的瓣膜植入成为可能。我们手术的特点是直接将瓣膜植入生物瓣瓣环(瓣中瓣),而不预先对人工瓣膜进行预扩张。